2023. március 2., csütörtök 09:00 |
DEBIOPHARM EXTENDS THEIR DNA DAMAGE REPAIR FOOTPRINT WITH NEW ONCOLOGY PIPELINE ENTRY (part 1) |
|
Lausanne, Switzerland, 2 March, 2023 (APA/OTS) - Debiopharm obtains global rights from Novo Nordisk for the development of their ubiquitin-specific protease 1 (USP1) inhibitor - Debiopharm (www.debiopharm.com), an independent Swiss-based, biopharmaceutical company aiming to develop tomorrow's standard-of-care treatments to cure cancer and infectious diseases, today announced having obtained the global rights for FT-3171, a small molecule USP1 inhibitor program targeting a novel DNA damage repair (DDR) pathway from Novo Nordisk. |
FT-3171 was developed by Forma Therapeutics, which was acquired by
Novo Nordisk in 2022, and is currently in late preclinical
development. FT-3171 (Debio 0432) could potentially be deployed to
combat multiple tumor types in poly ADP ribose pathway
inhibitor-sensitive and resistant settings.
This new pipeline entry will join WEE1-inhibitor Debio 0123,
reinforcing Debiopharm's commitment to improve cancer patients'
treatment response and to overcome treatment resistance to current
therapies. Through translational and eventual clinical
investigation, Debiopharm is poised to further apply their DDR
inhibitor expertise to efficiently advance the development of Debio
0432 with the ultimate aim of producing a novel therapy that
responds to unmet needs of cancer patients.
"In 2017, Debiopharm dove into the DDR inhibitor field, firstly
through its WEE1-inhibitor Debio 0123 and now through this
innovative asset, targeting USP1. We are eager to establish the
research necessary to bring this product to the clinical phase."
explained Angela Zubel, Chief Development Officer at Debiopharm.
"Leveraging the principle of synthetic lethality by inhibiting the
right DDR pathway targets to enable tumor cell destruction is an
emerging field that deserves further exploration, this target is
complementary with Debiopharm development pipeline like our ADC
programs or Debio 0123" mentioned Bertrand Ducrey, CEO, Debiopharm.
"We are thrilled about this licensing deal with Forma Therapeutics
and Novo Nordisk and evaluating the potential of this USP1-inhibitor
program."
About ubiquitin-specific protease 1 (USP1)
The USP family is one of the largest subfamily of deubiquitinases
(DUB).[1] Ubiquitin-specific protease 1 (USP1), in particular, is a
nucleus-localized enzyme and a well-established component of DNA
repair, acting both in the Fanconi Anemia pathway (on FANCD2 and
FANC1) and in translesion synthesis (TLS) on PCNA (Proliferating
Cell Nuclear Antigen) substrate. It catalyzes the removal of
specific monoubiquitin signals, is a critical regulator of genome
integrity and its dysfunction plays a key role in cancer initiation
and progression,[2-3] explaining why USP1 has recently drawn special
attention as cancer target. In addition, USP1 was recently
identified as a novel synthetic lethal interaction partner with
BRCA1 loss offering a good rationale for the investigation of USP1
inhibitors in patient populations currently treated with PARP
inhibitors.[4] The potential of this class of new therapeutic agents
might however be exploited in further settings as understanding of
USP1 biology is progressing.[5]
Debiopharm's commitment to patients Debiopharm aims to develop innovative therapies that target high
unmet medical needs in oncology and bacterial infections. Bridging
the gap between disruptive discovery products and real-world patient
reach, we identify high-potential compounds and technologies for
in-licensing, clinically demonstrate their safety and efficacy, and
then select large pharmaceutical commercialization partners to
maximize patient access globally.
For more information, please visit www.debiopharm.com We are on Twitter. Follow us @DebiopharmNews at
http://twitter.com/DebiopharmNews
Debiopharm Contact Dawn Bonine Head of Communications dawn.bonine@debiopharm.com Tel: +41 (0)21 321 01 11 (continues)
|
|
|
|
|
|
|
2023. március 2., csütörtök 09:00 |
DEBIOPHARM EXTENDS THEIR DNA DAMAGE REPAIR FOOTPRINT WITH NEW ONCOLOGY PIPELINE ENTRY (part 2) |
|
Lausanne, Switzerland, 2 March, 2023 (APA/OTS) - |
References
[1] Xu, Xin et al. Inhibition of Ubiquitin Specific Protease 1
Sensitizes Colorectal Cancer Cells to DNA-Damaging
Chemotherapeutics. Frontiers in oncology vol. 9 1406. 18 Dec. 2019,
doi:10.3389/fonc.2019.01406
[2] Pal, Anupama et al. Emerging potential of therapeutic targeting
of ubiquitin-specific proteases in the treatment of cancer. Cancer
research vol. 74,18 (2014): 4955-66.
doi:10.1158/0008-5472.CAN-14-1211
[3] Kah Suan Lim, Heng Li, Emma A Roberts, Emily F Gaudiano,
Connor Clairmont, Larissa Alina Sambel, Karthikeyan Ponnienselvan,
Jessica C Liu, Chunyu Yang, David Kozono, Kalindi Parmar, Timur
Yusufzai, Ning Zheng, Alan D D'Andrea. USP1 Is Required for
Replication Fork Protection in BRCA1-Deficient Tumors Mol Cell 2018
Dec 20;72(6):925-941 DOI: 10.1016/j.molcel.2018.10.045
[4] Are CRISPR Screens Providing the Next Generation of
Therapeutic Targets? Vazquez F, Sellers WR. Cancer Res. 2021 Dec 1;81(23):5806-5809.
doi: 10.1158/0008-5472.CAN-21-1784.
[5] USP1-trapping lesions as a source of DNA replication stress
and genomic instability Kate E Coleman, Yandong Yin, Sarah Kit Leng Lui, Sarah Keegan,
David Fenyo, Duncan J Smith, Eli Rothenberg, Tony T Huang Nat
Commun. 2022 Apr 1;13(1):1740. DOI: 10.1038/s41467-022-29369-3
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók
a forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI
által szó szerint továbbított tartalomért minden esetben a beadó a
felelős. © Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.
|
|
|
|
|
|
|
Forrás: OTS Üzleti Sajtószolgálat
MTI © Minden jog fenntartva.
|